# Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

> **NCT01150890** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 130 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Brodalumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01150890
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11-09
- **Primary completion:** 2011-10-15
- **Final completion:** 2011-10-15
- **Target enrollment:** 130 (ACTUAL)
- **Why stopped:** The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups
- **Last updated:** 2022-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01150890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01150890, "Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01150890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*